{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 10,
  "pageCount": 29,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a Kaplan-Meier curve to visually demonstrate the 'problem' (rapid progression) and a callout box to quantify the market opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/10",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Progression-free survival curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecd47784-6839-4efd-8be9-b83cabb06430",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "~60% of LBCL patients were observed to not achieve a durable response with CD19 CAR T-cell therapy. High unmet need with no standard of care for post CD19 CAR T patients and poor survival outcomes. By 2030, approximately 7,600 patients expected to need treatment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "834a850e-bd5e-4e34-8c06-8cfcfc6f3287",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Five-year follow-up of ZUMA-1 trial; (1) N Engl J Med 2017;377:2531-44 DOI: 10.1056/NEJMoa1707447; (2) Clarivate Disease and Landscape Forecasting (NHL, CLL) 2023; US/EU4/UK and CARGO company analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e43dbaa2-3a74-4003-8c70-c9fe96d1b11d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "For patients whose disease R/R to CD19 CAR T-cell therapy, lead product candidate CRG-022 could address a significant and growing unmet need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "959d4fc2-ad47-4cc4-8861-2e640e6f04fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "62e11845-861c-4c0e-a84a-4a131fb98c5c",
      "evidence": "Frames the current poor outcome (before) as the problem to be solved by the candidate (after).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "a9f20cbe-143f-496d-bc90-e53c6de8c8f4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slide 10 presents the problem statement",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06",
      "evidence": "The loop is opened on slide 10 and closed on slides 12-15",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}